Cargando…
iPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy
Recent advances in induced pluripotent stem cell (iPSC) technology and directed differentiation of iPSCs into cardiomyocytes (iPSC-CMs) make it possible to model genetic heart disease in vitro. We apply CRISPR/Cas9 genome editing technology to introduce three RBM20 mutations in iPSCs and differentia...
Autores principales: | Briganti, Francesca, Sun, Han, Wei, Wu, Wu, Jingyan, Zhu, Chenchen, Liss, Martin, Karakikes, Ioannis, Rego, Shannon, Cipriano, Andrea, Snyder, Michael, Meder, Benjamin, Xu, Zhenyu, Millat, Gilles, Gotthardt, Michael, Mercola, Mark, Steinmetz, Lars M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168789/ https://www.ncbi.nlm.nih.gov/pubmed/32905764 http://dx.doi.org/10.1016/j.celrep.2020.108117 |
Ejemplares similares
-
RBM20-Related Cardiomyopathy: Current Understanding and Future Options
por: Koelemen, Jan, et al.
Publicado: (2021) -
RBM20 phosphorylation and its role in nucleocytoplasmic transport and cardiac pathogenesis
por: Zhang, Yanghai, et al.
Publicado: (2022) -
Reducing RBM20 activity improves diastolic dysfunction and cardiac atrophy
por: Hinze, Florian, et al.
Publicado: (2016) -
Mislocalization of pathogenic RBM20 variants in dilated cardiomyopathy is caused by loss-of-interaction with Transportin-3
por: Kornienko, Julia, et al.
Publicado: (2023) -
New Insights in RBM20 Cardiomyopathy
por: Lennermann, D., et al.
Publicado: (2020)